دورية أكاديمية
Intravenous colistin in the treatment of multidrug-resistant gram-negative organism in tertiary hospital, Jazan, KSA.
| العنوان: | Intravenous colistin in the treatment of multidrug-resistant gram-negative organism in tertiary hospital, Jazan, KSA. |
|---|---|
| المؤلفون: | Ali EM; Department of Clinical Pharmacy, Jazan University, Jazan, Saudi Arabia., Albarraq AA; Department of Clinical Pharmacy, Pharmacy Practice Research Unit, College of Pharmacy, Jazan Univerity, Jazan, Saudi Arabia., Makeen HA; Department of Clinical Pharmacy, Pharmacy Practice Research Unit, College of Pharmacy, Jazan Univerity, Jazan, Saudi Arabia., Ezzi A; Senior Pharmacist in KFCH, Jazan, Saudi Arabia., Mashragi YAM; Senior Pharmacist in KFCH, Jazan, Saudi Arabia. |
| المصدر: | Journal of family medicine and primary care [J Family Med Prim Care] 2021 Jan; Vol. 10 (1), pp. 333-338. Date of Electronic Publication: 2021 Jan 30. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Medknow Country of Publication: India NLM ID: 101610082 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2249-4863 (Print) Linking ISSN: 22494863 NLM ISO Abbreviation: J Family Med Prim Care Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Mumbai : Medknow |
| مستخلص: | Background: It was considered that the resistance of drugs such as carbapenems and cephalosporins against severe or high risk gram-negative bacteria became a tremendous confront. This might be attributed to the little amount of these drugs to be used against the multi-resistant bacteria (MRB). Therefore, Colistin, Fosfomycin, Temocillin, and Rifampicin are antibiotics that have been used as multidrug-resistant bacterial infections in the treatment of some species of bacteria such as Acinetobacter, Pseudomonas species, and Enterobacteriaceae. Aim: the present study is aimed to assess the integrity and efficiency of colistin for treating of the multidrug-resistant bacteria (MDR) especially gram-negative one among critical and non-critical patients in tertiary hospital in Jazan city. Ninety four patients who met the selection criteria and received colistimethate sodium (colistin) in the period between Februarys 2017 and March 2018 were recruited and their charts were reviewed retrospectively. Patients' information, medical conditions, and laboratory data were extracted. All patients received IV colistin, and the majority of the patients showed in their culture reports multidrug-resistant bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii. Patients who had normal renal function received from 2.5 to 5.0 mg of colistin/kg, which was divided in two or three doses intravenously, for duration ranging between 10 and 14 days. Results and Conclusion: Approximately half of patients (48.93%) were fully recovered, while 19% of them were partially responded to colistin treatment. In the current study it was showed that IV colistin treatment against the multidrug-resistant bacteria (gram-negative bacteria) was strongly related to mild nephrotoxicity in addition to with a proper response as shown only in three of our patients. Competing Interests: There are no conflicts of interest. (Copyright: © 2021 Journal of Family Medicine and Primary Care.) |
| References: | Int J Antimicrob Agents. 2010 Feb;35(2):194-9. (PMID: 20006471) Int J Infect Dis. 2020 Apr;93:9-14. (PMID: 31978579) Clin Infect Dis. 2005 May 1;40(9):1333-41. (PMID: 15825037) Int J Infect Dis. 2007 Sep;11(5):402-6. (PMID: 17291803) Pharmacol Ther. 2018 Jan;181:85-90. (PMID: 28750947) Can J Infect Dis Med Microbiol. 2008 Nov;19(6):413-8. (PMID: 19436571) Crit Care. 2003 Oct;7(5):R78-83. (PMID: 12974973) Crit Care. 2006 Feb;10(1):R27. (PMID: 16507149) Int J Infect Dis. 2013 Dec;17(12):e1130-3. (PMID: 24021566) Antimicrob Agents Chemother. 2006 Jun;50(6):1953-8. (PMID: 16723551) Antimicrob Agents Chemother. 2010 Dec;54(12):4971-7. (PMID: 20855724) Pharmaceuticals (Basel). 2020 Mar 06;13(3):. (PMID: 32155714) J Clin Pharmacol. 2001 Jun;41(6):645-54. (PMID: 11402633) Antimicrob Agents Chemother. 2007 Jun;51(6):1905-11. (PMID: 17387153) Infect Dis Clin North Am. 2004 Sep;18(3):669-89, x. (PMID: 15308281) Clin Infect Dis. 1999 May;28(5):1008-11. (PMID: 10452626) Antibiotics (Basel). 2020 Aug 06;9(8):. (PMID: 32781593) |
| فهرسة مساهمة: | Keywords: Colistimethate sodium; intravenous colistin; multidrug resistant gram negative bacteria (MDR); nephrotoxicity |
| تواريخ الأحداث: | Date Created: 20210521 Latest Revision: 20220423 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC8132804 |
| DOI: | 10.4103/jfmpc.jfmpc_1148_20 |
| PMID: | 34017749 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2249-4863 |
|---|---|
| DOI: | 10.4103/jfmpc.jfmpc_1148_20 |